IVDT_In Vitro Diagnostics Technology

IVD Technology, Spring 2013

Issue link: http://dc.cn.ubm-us.com/i/125322

Contents of this Issue


Page 26 of 43

ASSAY DEVELOPMENT developing better quality antibodies. Several RabMAbs to these targets are under development through the collaboration between Epitomics and IVD companies. In addition, glycomics and lipidomics are emerging scientifc disciplines for understanding the biological and pathological functions of lipids, glycolipids, and carbohydrates at the cellular and organismal levels. RabMAb will be an important research tool, and some RabMAbs may have diagnostic applications. Viruses usually undergo mutation and selection and gradually change their structure to avoid the surveillance of the host immune system. Tese changes lead to alterations in the antigenicity of the virus, called antigenic drift. Tis, in turn, makes clinical diagnosis more difcult. Parasitic protozoa can also manage to survive within their host by altering surface antigens rapidly and repeatedly, as well. Te larger antibody repertoire derived from rabbit ofers a better chance to zoom in on ivd tech n o lo gy.com magenta cyan yellow black such subtle changes in epitopes and develop better diagnostic reagents in comparison with mouse antibody technology. Tis has been demonstrated by a few cases (data not shown). Immunoassays for cancer and cardiac markers. In real biological samples, such as blood, serum or urine, target antigens are more complicated than purifed immunogens. Tese antigens could exist as free forms, chemically modifed variants, complexes with other proteins, or degraded fragments. In addition, the challenge involving immunoassay standardization is mainly caused by epitope variability, the matrix efect, and the lack of dynamic linear range of antibody and antigen interaction. A signifcant number of cancer antigens are glycoproteins on tumor cell surfaces such as CA-50, CA-153, CA-199, and CA72-4, and many antibodies actually recognize the carbohydrate epitopes on the glycoproteins instead of protein. Developing more-sensitive or specifc antibodies to these carbohydrate epitopes will lead to better or novel diagnoses. In the cardiac disease diagnostic area, more-sensitive and specifc antibodies to Troponin I, BNP (B-type natriuretic peptide), and D-dimer are needed for better or early detection of acute coronary syndrome, congestive heart failure, and thrombotic disorders. Typically, antigens isolated from patient body fuids are a better source for developing high-quality antibodies, and clinical sample screening is also necessary to identify the appropriate clones. We believe the new form of antibody, RabMAb technology, will change the diagnostic landscape when more best-in-class antibodies are developed and incorporated into medical devices. Conclusion Te rabbit immune system generates antibody diversity and optimizes afnity through mechanisms that are more efcient than those of mice and other rodents. Tis increases I VD T EC H N O LO G Y | S PR I NG 2 0 1 3 2 7 ES236231_IV1305_027.pgs 04.23.2013 23:41 UBM

Articles in this issue

Links on this page

Archives of this issue

view archives of IVDT_In Vitro Diagnostics Technology - IVD Technology, Spring 2013